GOSS - Gossamer Bio, Inc.

QQQ $ 445.88 $ 2.85 (0.64 %)

DIA $ 395.58 $ 1.12 (0.28 %)

SPY $ 523.16 $ 2.39 (0.46 %)

TLT $ 90.86 $ 0.51 (0.56 %)

GLD $ 218.12 $ 1.83 (0.85 %)

Previous Close

$ 0.7328

Open

$ 0.71

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 0.71 - $ 0.74

52 Week Range

$ 0.45 - $ 1.88

Volume

2,608,330

Average Volume

Market Cap

165.42M

Beta (5Y Monthly)

$ 1.26

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-07-2024	03-31-2024	10-Q
2	03-05-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-08-2023	06-30-2023	10-Q
5	05-09-2023	03-31-2023	10-Q
6	03-17-2023	12-31-2022	10-K
7	11-03-2022	09-30-2022	10-Q
8	08-09-2022	06-30-2022	10-Q
9	05-10-2022	03-31-2022	10-Q
10	03-03-2022	12-31-2021	10-K
11	11-08-2021	09-30-2021	10-Q
12	08-09-2021	06-30-2021	10-Q
13	05-06-2021	03-31-2021	10-Q
14	02-26-2021	12-31-2020	10-K
15	11-10-2020	09-30-2020	10-Q
16	08-11-2020	06-30-2020	10-Q
17	05-12-2020	03-31-2020	10-Q
18	03-24-2020	12-31-2019	10-K
19	11-12-2019	09-30-2019	10-Q
20	08-08-2019	06-30-2019	10-Q
21	05-14-2019	03-31-2019	10-Q
22	03-22-2019	12-31-2018	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Gossamer Bio Provides Updated Seralutinib ...
05/14/2024 20:15:56

Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization o...

12-health-care-stocks-moving-in-mondays-after-market-session

12 Health Care Stocks Moving In Monday's A...
05/13/2024 20:31:07

Wedbush Reiterates Outperform on Gossamer ...
05/08/2024 14:19:14

Wedbush analyst Laura Chico reiterates Gossamer Bio (NASDAQ:GOSS) with a Outperform and maintains $4 price target.

Gossamer Bio Q1 EPS $(0.19) Misses $(0.18)...
05/07/2024 20:48:04

Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.18...

gossamer-bio-collaborates-with-italian-drugmaker-chiesi-to-advance-lung-health-solutions-worldwide

Gossamer Bio Collaborates With Italian Dru...
05/06/2024 17:17:19

Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hyperte...

HC Wainwright & Co. Reiterates Buy on Goss...
05/06/2024 16:16:31

HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...

Watching Gossamer Bio; Traders Circulate U...
05/06/2024 14:40:28

Trading Halt: Halt status updated at 7:55:...
05/06/2024 11:55:07

Gossamer Bio Secures $160M Partnership wit...
05/06/2024 11:37:40

Gossamer Bio, Inc. ("Gossamer") (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development an...

Trading Halt: Halted at 7:25:00 a.m. ET - ...
05/06/2024 11:25:04

Gossamer Bio Published TORREY Phase 2 Resu...
05/03/2024 12:02:56

12-health-care-stocks-moving-in-thursdays-after-market-session

12 Health Care Stocks Moving In Thursday's...
04/25/2024 20:32:50

12-health-care-stocks-moving-in-fridays-after-market-session

12 Health Care Stocks Moving In Friday's A...
04/05/2024 20:31:09

Wedbush Assumes Gossamer Bio at Outperform...
04/05/2024 08:57:25

Wedbush analyst Laura Chico assumes Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announces Price Target of $4.

Piper Sandler Maintains Overweight on Goss...
03/27/2024 16:43:02

Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and maintains $15 price target.

Goldman Sachs Maintains Buy Rating for Gos...
03/06/2024 17:00:20

Goldman Sachs Maintains Buy on Gossamer Bi...
03/06/2024 16:36:33

Goldman Sachs analyst Paul Choi maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and lowers the price target from $9 to $8.

Wedbush Reiterates Outperform on Gossamer ...
03/06/2024 16:11:39

Wedbush analyst Andreas Argyrides reiterates Gossamer Bio (NASDAQ:GOSS) with a Outperform and maintains $6 price target.

HC Wainwright & Co. Reiterates Buy on Goss...
03/06/2024 13:44:27

HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...

Gossamer Bio Q4 EPS $(0.21), Inline; Cash,...
03/05/2024 12:36:09

Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 6...